Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Blood contains a mixture of exosomes secreted from nearly all tissues and cells, and exosomes from other tissues can mask changes caused by disease, making it difficult to detect the presence of biomarkers that reflect disease
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
he financing was significantly oversubscribed with high demand from both existing and new investors.
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease
Subscribe To Our Newsletter & Stay Updated
